Medicon Valley Biomedical Newsletter

A research group from the Department of Medical Biochemistry and Genetics at Copenhagen University has entered into collaboration with Santaris Pharma A/S for the development of more efficient pharmac...

The Swedish Foundation for Strategic Research has granted five centres in Lund EUR 21 million for a five-year period. One of the centres is located at Lund University, where Professor Patrik Rorsman a...

Active Biotech AB has commenced screening of patients in a Phase I clinical trial of the 57-57 Project for systemic lupus erythematosus, SLE. Also patients with rheumatoid arthritis, RA, will be inclu...

AstraZeneca has announced an agreement to acquire KuDOS Pharmaceuticals Limited, a privately owned UK biotechnology company, focused on the discovery and development of oncology therapies based on the...

AstraZeneca has signed an exclusive global licensing and research collaboration agreement with US-based Targacept Inc. for the development and commercialisation of Targacept's Phase II compound, T...

BioGaia has signed an agreement with the American company Victus Inc, with whom BioGaia already has a cooperation regarding distribution of a Reuteri product containing the probiotic lactic acid bacte...

BioInvent International AB has announced that the US Patent Office has granted a new patent covering its n-CoDeR antibody library. The issued patent covers methods for preparation of ...

Gambro BCT, a business area belonging to Gambro AB, has initiated a human clinical study in France of its pathogen reduction system for platelets, Mirasol. The study will include approximately 120 thr...

Genmab A/S has announced that HuMax-EGFr has been designated a Fast Track Product by the FDA. This designation covers patients with head and neck cancer who have previously failed standard therapies. ...

Leo Pharma A/S has announced that the drug Taclonex has been approved by the FDA for sale in the US. Taclonex is a topical treatment of psoriasis in adults and is marketed as Dovobet or Daivobet outsi...

H. Lundbeck A/S has announced that Serdolect is available in the first country in Europe - Estonia. This is the first launch of Serdolect, which received marketing approval for the treatment of schizo...

NeuroSearch A/S has initiated a clinical Phase I/II study with the AMPA antagonist NS1209 for the treatment of neuropathic pain. Necessary approvals from the authorities and the ethical committees hav...

Pharmexa A/S has obtained the required regulatory approvals for the Phase II trial with the HER-2 Protein AutoVac breast cancer vaccine in combination with the adjuvant QS-21 in Russia and the doctors...

Pharmexa A/S's Norwegian subsidiary GemVax collaborates with Ullevål University Hospital on translational research of immunotherapy in combination with different treatment regimens ...

Symphogen A/S has announced the initial closing of a EUR 20,7 million Series D financing at a premium to the last financing round. The financing will be used to carry out clinical trials of Symphogen...

TopoTarget A/S has entered an agreement with an undisclosed pharmaceutical company with a strong presence and track record in the named markets, for the promotion of Savene in the treatment of the acc...

TopoTarget A/S and BioImage A/S have entered an agreement under which TopoTarget acquires the exclusive right to full ownership of a BioImage preclinical anticancer drug programme. The...

ZGene A/S and US-based Lentigen Corporation have entered into an agreement whereby Lentigen will obtain an exclusive license to specified proprietary ZGene multisubstrate kinase genes for certain indi...

The European Patent Office has notified Zymenex A/S of the decision to grant Zymenex a European Patent on the "Production of rhPBGD". This patent covers the production method for Zymenex's l...